Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc, dated December 18, 2025, reports on a best efforts public offering commenced on December 17, 2025. The company, a foreign private issuer based in Cardiff, United Kingdom, is raising capital to fund development programs and working capital.
Key Financial Metrics
- Offering Proceeds: Expected net proceeds of approximately $8.75 million after deducting fees and expenses, excluding potential proceeds from warrant exercises.
- Cash Position: As of September 30, 2025, the company held cash and cash equivalents of £2.79 million. This figure is unaudited.
- Offering Structure:
- 157,000 ADS Units at $3.28 per unit (1 ADS + 2 Series L Warrants).
- 2,891,781 Pre-Funded Units at $3.2799 per unit (1 Pre-Funded Warrant + 2 Series L Warrants).
- Warrant Terms: Series L Warrants have an exercise price of $3.28 and expire five years post-issuance. Pre-Funded Warrants have an exercise price of $0.0001 and are immediately exercisable.
- Placement Agent Fees: Maxim Group LLC received a cash fee of 7.0% of gross proceeds, reimbursement of expenses up to $100,000, and warrants to purchase 152,439 ADSs.
Material Changes
The primary material change is the initiation of the equity offering, which will significantly increase the company's share count. Assuming the closing of the offering and no exercise of warrants, the company will have 83,878,708,922 Ordinary Shares outstanding. Additionally, a previously disclosed dispute with a former advisor regarding fees was resolved via a settlement payment made on September 29, 2025.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds will be used for development programs, working capital, and general corporate purposes.
- Closing Timeline: The offering is anticipated to close on or about December 19, 2025.
- Lock-Up Provisions: The company agreed not to issue new securities for 45 days post-closing and is restricted from variable rate transactions for 180 days post-closing.
- Risks: Forward-looking statements regarding the closing and proceeds are subject to risks, including the ability to satisfy closing conditions and market volatility. The financial data provided for September 30, 2025, is unaudited and should not be relied upon unduly.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $8.75 million.
- Confirm the exact number of shares outstanding post-offering, accounting for any immediate exercise of Pre-Funded Warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific conditions to closing and indemnification obligations.
- Monitor the company's cash burn rate relative to the £2.79 million cash balance reported as of September 30, 2025.
- Check for any subsequent filings regarding the exercise of Series L Warrants or Placement Agent Warrants.